Year-to-Date Revenue Declined by 2.8% at Constant Exchange Rate (CER), 3.3% at Actual Exchange Rates (AER); Impact of VYVANSE Generics is Tapering Off
Core Operating Profit Declined by 3.4% at both CER and AER Year to Date
Reported Operating Profit Increased by 1.2% at AER Year to Date, Lower Restructuring Expenses More Than Offset Impairment
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2025 (nine months ended December 31, 2025). The gap between incremental Growth & Launch Products revenue and VYVANSE erosion is narrowing, and operational efficiencies drove year-on-year reductions in operating expenses, including R&D. The company raised its full-year forecasts based on cost discipline and FX tailwind, while its Revenue Management Guidance has been updated primarily due to the impact of VYVANSE generics.
Takeda is positioned for long-term growth and has multiple late-stage programs with multibillion-dollar peak revenue potential. Following the positive readouts from Phase 3 studies in 2025, the company has submitted New Drug Applications (NDAs) for oveporexton and rusfertide and is on track to file an NDA for zasocitinib. Each of these programs, which Takeda expects to launch within the next 18 months, has the potential to redefine standards of care, transform patient lives and contribute to Takeda's new growth trajectory.
Takeda chief financial officer, Milano Furuta, commented:
“While we manage the impact of VYVANSE generics, we are implementing disciplined cost management and improving operational efficiency and therefore expect to achieve the previously disclosed Management Guidance for Core Operating Profit.
“FY2025 remains a truly pivotal year for Takeda as we are in a phase of preparing for significant new product launches. Looking ahead, with multiple innovative launches and a robust late-stage pipeline, Takeda is positioned to bring life-transforming medicines that improve patient lives and deliver long-term shareholder value.”
FINANCIAL HIGHLIGHTS for FY2025 Q3 YTD Ended December 31, 2025
|
(Billion yen, except percentages and per share amounts) |
||||
|
Item |
FY2025 Q3 YTD |
FY2024 Q3 YTD |
vs. PRIOR YEAR (Actual % change) |
|
|
Revenue |
3,411.2 |
3,528.2 |
-3.3% |
|
|
Operating Profit |
422.4 |
417.5 |
+1.2% |
|
|
Net Profit |
216.1 |
211.1 |
+2.4% |
|
|
EPS (Yen) |
137 |
134 |
+2.7% |
|
|
Operating Cash Flow |
966.9 |
835.0 |
+15.8% |
|
|
Adjusted Free Cash Flow (Non-IFRS) |
625.9 |
568.3 |
+10.1% |
|
